High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
about
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaAddition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II studyRandomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMADecitabine for acute myeloid leukemia.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyNew considerations in the design of clinical trials for the treatment of acute leukemia.The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinTargeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Acute myeloid leukaemia in the elderly: a review.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.Current strategies in immunotherapy for acute myeloid leukemia.New therapeutic approaches to acute myeloid leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Gemtuzumab ozogamicin in acute myeloid leukemia.Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?Outcome of older patients with acute myeloid leukemia in first relapse.Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Improving consolidation therapy in acute myeloid leukemia - a tough nut to crackApplications of monoclonal antibodies for the treatment of hematological malignanciesFractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French associationRecent advances in the understanding and treatment of acute myeloid leukemia
P2860
Q27853019-8A03FFC9-326F-414E-8BDF-A7FC3A3D20F1Q30835785-BD67EAD2-5E08-4175-BC76-65704E9906E5Q33281867-FE49E727-8759-44B7-AF18-E43E4AD5C886Q33412354-EE3E091D-C512-4844-8C3A-BFF3119804B2Q33558088-FF029D87-48A8-4F18-BE81-B5D7F70950A7Q33828797-ADE4614C-897D-4BEB-A1A4-B14785E6D400Q34257184-422AFC26-5BE8-425C-82AA-0FC084D7BCE6Q36058588-42478318-A651-401F-8BDC-971C42F1F824Q36641721-3AB0E30C-A066-4C3B-BC01-1A29A639C4DBQ36832124-52F94007-F62E-4AEE-96E0-98FF21116FEBQ36932014-CEA9522F-27E7-450A-AEC2-472CC423EE6DQ37199950-A41216EA-487A-4B94-8207-70EC683CB9C3Q37381414-B2D98666-B4F7-4173-95BB-D7E5D44F312DQ37840260-7E3F3D27-B246-4F58-BC7E-A2B9EE84170BQ37910260-386B413A-BC66-499F-ACD6-6DBD332F860AQ38042401-68FF84DC-86D9-45E1-BBA4-F19474ABB4BBQ38068967-2A93D9F2-19F6-4635-B57D-7432CCD5158EQ38090673-ABABB9C4-DB83-4158-9204-B3B8E160F86BQ38109541-2D0C83FA-7A9A-4184-8316-A0B3CEEC9678Q38728718-8DBC9FB1-E4CF-4AB8-8F3E-76B54256A029Q39067366-53D0B609-6747-4F9A-9289-9046251E56BFQ39405204-162AAAD8-F9E1-4E10-A648-8A67ED647C1CQ39964227-127D459D-AC33-489A-A233-989FFB5907D4Q40872029-ACFE142E-0724-405C-B639-50861BC41C96Q42357653-E01685F1-A3D4-441F-97C3-ED6CFCEC69A0Q44073282-67157842-6CA7-419E-9303-8180ECD7D7CFQ44462005-2CD58CCE-19EB-4ED2-AF99-25D3B676F086Q48349415-9FD15186-F7FE-42AC-AACC-E97E2069A208Q54956859-AE2FF868-8929-4411-B39A-F7ADAA9B4D1FQ57055454-7F349BBE-8072-47F2-A9C2-4EB4724701D4Q57904664-5D6E0E93-CDBA-43DB-AB83-53750EC76B1AQ58415977-C47E4626-998E-48BE-8445-688E7D40768FQ58799330-7ED8CCBB-9DE5-4686-A332-A843C2EFF258
P2860
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High efficacy and safety profi ...... ctive study of the alfa group.
@ast
High efficacy and safety profi ...... ctive study of the alfa group.
@en
type
label
High efficacy and safety profi ...... ctive study of the alfa group.
@ast
High efficacy and safety profi ...... ctive study of the alfa group.
@en
prefLabel
High efficacy and safety profi ...... ctive study of the alfa group.
@ast
High efficacy and safety profi ...... ctive study of the alfa group.
@en
P2093
P2860
P356
P1433
P1476
High efficacy and safety profi ...... ctive study of the alfa group.
@en
P2093
A-L Taksin
N Contentin
P2860
P2888
P356
10.1038/SJ.LEU.2404434
P577
2006-10-19T00:00:00Z
P5875
P6179
1008085123